Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CervoMed (CRVO)
NASDAQ:CRVO
Holding CRVO?
Track your performance easily
CRVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $26.38
Previous CloseN/A
Volume72.82K
Average Volume (3M)759.90K
Market Cap
$17.42M
Enterprise Value$80.40M
Total Cash (Recent Filing)$1.55M
Total Debt (Recent Filing)$550.00K
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Apr 07, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding8,253,741
10 Day Avg. Volume201,776
30 Day Avg. Volume759,898
Standard Deviation0.35
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.70
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap4.62
Enterprise Value/Revenue5.46
Enterprise Value/Gross Profit11.25
Enterprise Value/Ebitda-12.52
Forecast
1Y Price Target
$8.00Price Target Upside279.15% Upside
Rating ConsensusHold
Number of Analyst Covering8
CervoMed News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNeflamapimod displayed a favorable safety and tolerability profile that is consistent with prior clinical studies, with no new safety signal identified.
Financial PositionCervoMed ended with $46.7M in cash and cash equivalents, which should provide the company with some strategic optionality regardless of the ultimate fate of neflamapimod.
Market PotentialNeflamapimod could achieve blockbuster status within only four or five years of launch, with expected market exclusivity until 2039.
Bears Say
Clinical Trial ResultsThe trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) or any of its key secondary endpoints.
Drug Development UncertaintyOutstanding uncertainty for neflamapimod development in DLB and limited catalysts beyond the OLE data lead to a downgrade of CRVO shares to Underweight.
Financial PerformanceThe stock is now trading below cash, which CRVO now expects to last until mid-26E as it is pausing previously planned Phase 3 activity.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $1.80 and its highest was $26.38 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $17.42M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Apr 07, 2025 which is in 79 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Nov 12, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.138.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.62.
How many shares outstanding does CervoMed have?
CervoMed has 8,253,741 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went down -2.554%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
---
Company Description
CervoMed
Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
---
CRVO Stock 12 Month Forecast
Average Price Target
$8.00
▲(279.15% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Aldeyra Therapeutics
―
EyePoint Pharmaceuticals
―
Kala Pharmaceuticals
―
Omeros
―
CytomX Therapeutics
―
Best Analysts Covering CRVO
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-76.91%
reiterated a buy rating last month
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -76.91% per trade.
---